We found the concurrent expression of oncogenic KRAS and mutant TP53 in the imPAC2 cells led to the formation of subcutaneous masses with high proliferative activity even in the absence of the 3D PPCNg scaffold, and upregulated the expression of the members of the PI3K/AKT/mTOR pathway and lung cancer-related genes in vivo. This evidence concerns the gene KRAS and lung carcinoma.